Abstract 284TiP
Background
Landmark trials have established a survival benefit for novel hormonal agents (NHA) added to androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). Yet, there is a significant medical need to expand therapeutic options, especially for pts with high-risk mHSPC who experience poorer outcomes. Abemaciclib is an oral selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6) dosed on a continuous schedule and approved for the treatment of node-positive high-risk early-stage and advanced or metastatic HR+, HER2− breast cancer. Analogous to the estrogen receptor signaling pathway in breast cancer, there is evidence that the androgen receptor axis activates CDK4/6 to sustain prostate cancer cell proliferation, and upregulation of cyclin D1 is a potential mechanism of resistance to NHA therapy. In preclinical models, abemaciclib induces cell cycle arrest and inhibition of prostate tumor growth.
Trial design
CYCLONE 3 is a global, randomized, double-blind, placebo-controlled study evaluating the addition of abemaciclib to abiraterone+prednisone (AP) in pts with high-risk mHSPC. Approximately 900 pts with high-risk mHSPC defined by ≥4 bone metastases and/or visceral disease will be randomised in a 1:1 ratio to the AP + abemaciclib or AP + placebo arm. Up to 3 months of ADT prior to randomization is permitted; prior docetaxel for mHSPC is excluded. Pts who has not undergone orchiectomy will continue ADT. Stratification factors are de novo mHSPC and visceral metastases. Primary endpoint is investigator-assessed radiographic progression-free survival (rPFS). Key secondary endpoints include rPFS assessed by blinded independent central review, castration-resistant prostate cancer-free survival, overall survival, time to pain progression, safety and pharmacokinetics. Approximately 270 sites across 24 countries are participating, including in Asia. Updated from abstract previously presented at European Society for Medical Oncology (ESMO) 2022, FPN (Final Publication Number): 2189, Rana McKay et al. Reused with permission.
Clinical trial identification
NCT05288166.
Editorial acknowledgement
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
N. Matsubara: Other, Personal and Institutional, Advisory Role, Honoraria, Speakers’ bureau, Research funding: Janssen, MSD; Other, Personal and Institutional, Research Funding, Honoraria: Taiho; Other, Personal and Institutional, Advisory Role, Research funding: Bayer, Roche; Other, Personal and Institutional, Advisory Role, Speakers’ bureau: Sanofi; Other, Personal and Institutional, Speaker’s Bureau: AstraZeneca. N. Agarwal: Other, Personal and Institutional, Advisory Role: Eli Lilly & Company, Janssen, Pfizer, Bayer, Amgen, Novartis, Bristol Myers Squibb, Astellas Pharma, AstraZeneca, ORIC Pharmaceuticals, Nektar, Pharmacyclics, Foundation Medicine, Eisai, AVEO; Other, Personal, Advisory Role: Calithera Biosciences, MEI Pharma, Gilead Sciences, Takeda. M.R. Smith: Other, Personal and Institutional, Advisory Role, Honoraria, Research Funding: Astellas Pharma, Bayer, Pfizer, Janssen, Lilly; Other, Personal and Institutional, Research Funding: Arvinas. R.R. McKay: Financial Interests, Personal, Research Funding, Consulting or Advisory Role: Bayer, Pfizer, Tempus; Financial Interests, Personal, Advisory Role: Astellas Medivation, AstraZeneca, Aveo, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novartis, Sanofi. T. Todenhöfer: Financial Interests, Personal, Advisory Role: Eli Lilly and Company, Janssen, Pfizer, Bayer, Novartis, Amgen, Bristol Myers Squibb, Astellas Pharma, AstraZeneca, Roche, Ipsen, Basilea. J.M. Piulats Rodriguez: Financial Interests, Personal, Advisory Role: Pfizer, Janssen, Bristol Myers Squibb, Merck, Roche, AstraZeneca, Astellas Pharma, Clovis Oncology, VCN Biosciences, Incyte, EMD Serono, BeiGene. K.L. Chung, D. Heirich, S. Sherwood, C. Schaverien, N. Fasnacht, A. Lithio, K. Nacerddine: Financial Interests, Personal, Other, Employee and Shareholder: Eli Lilly and Company. All other authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract